Ken Griffin
XERS icon

Ken Griffin’s Xeris Biopharma Holdings XERS Stock Holding History

Ken Griffin’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Buy
681,634
+271,814
+66% +$1.8M ﹤0.01% 4732
2025
Q4 		$3.22M Sell
409,820
-27,792
-6% -$219K ﹤0.01% 5045
2025
Q3 		$3.56M Buy
+437,612
New +$2.91M ﹤0.01% 4978
2025
Q2 		– Sell
-1,347,859
Closed -$6.18M – 15390
2025
Q1 		$7.4M Buy
1,347,859
+514,531
+62% +$2.08M ﹤0.01% 3287
2024
Q4 		$2.82M Buy
+833,328
New +$2.68M ﹤0.01% 4938
2024
Q2 		– Sell
-95,348
Closed -$192K – 15559
2024
Q1 		$211K Sell
95,348
-305,229
-76% -$790K ﹤0.01% 10203
2023
Q4 		$941K Buy
400,577
+371,383
+1,272% +$685K ﹤0.01% 6795
2023
Q3 		$54.3K Buy
+29,194
New +$66.9K ﹤0.01% 11665
2023
Q1 		– Sell
-21,240
Closed -$26.6K – 15609
2022
Q4 		$28.2K Sell
21,240
-14,910
-41% -$21K ﹤0.01% 12807
2022
Q3 		$57K Sell
36,150
-52,173
-59% -$86.3K ﹤0.01% 11535
2022
Q2 		$136K Sell
88,323
-54,891
-38% -$116K ﹤0.01% 11082
2022
Q1 		$366K Buy
143,214
+28,867
+25% +$70.5K ﹤0.01% 10134
2021
Q4 		$335K Buy
114,347
+38,513
+51% +$83.2K ﹤0.01% 10684
2021
Q3 		$186K Buy
75,834
+1,592
+2% +$4.62K ﹤0.01% 12091
2021
Q2 		$302K Sell
74,242
-33,820
-31% -$129K ﹤0.01% 11261
2021
Q1 		$487K Buy
108,062
+49,265
+84% +$266K ﹤0.01% 9736
2020
Q4 		$289K Buy
58,797
+35,391
+151% +$177K ﹤0.01% 9145
2020
Q3 		$139K Sell
23,406
-8,982
-28% -$35.9K ﹤0.01% 9052
2020
Q2 		$86K Buy
+32,388
New +$113K ﹤0.01% 9077
2019
Q2 		– Sell
-29,941
Closed -$301K – 9955
2019
Q1 		$301K Buy
+29,941
New +$384K ﹤0.01% 7608
2018
Q3 		– Sell
-11,290
Closed -$214K – 9760
2018
Q2 		$214K Buy
+11,290
New +$219K ﹤0.01% 7782

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ken Griffin's XERS Position: Q1 2026 in Review

Ken Griffin increased its Xeris Biopharma Holdings (XERS) stake by 66% in Q1 2026, buying an estimated $1.8M and bringing the position to 681,634 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Ken Griffin first reported a position in XERS in Q2 2018 and has held it in 21 quarters since. The position peaked at $7.4M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Ken Griffin held 681,634 shares of Xeris Biopharma Holdings worth $3.95M as of Q1 2026.
  • Ken Griffin bought 271,814 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.8M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4732 holding.
  • Ken Griffin first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 21 quarters since.
  • Ken Griffin's Xeris Biopharma Holdings position peaked at $7.4M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.